Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone

ABSTRACT Severe acute respiratory syndrome coronavirus 2 has caused a global pandemic, leading to health, economic, and political crisis. The virus triggers the activation of inflammatory reactants including interleukin-6 (IL-6), ferritin, and C-reactive protein (CRP), causing multiorgan damage, par...

Full description

Bibliographic Details

Published in:	Microbiology Spectrum
Main Authors:	Carolina Calderón-Ochoa, Narek Plamenov-Donchev, Fernando Hernández-Quiñones, Olga Mendoza-López, Luis Carlos Hinojos-Gallardo, Asunción José Longino-Gómez, Raúl Hernádez-Saldaña, Jorge Duque-Rodríguez, María Cecilia Ishida-Gutiérrez
Format:	Article
Language:	English
Published:	American Society for Microbiology 2024-06-01
Subjects:	COVID-19 C reactive protein interleukin 6 tocilizumab
Online Access:	https://journals.asm.org/doi/10.1128/spectrum.02498-23